The Manufacturers Life Insurance Company Sells 20,029 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

The Manufacturers Life Insurance Company lessened its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 15.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 106,215 shares of the company's stock after selling 20,029 shares during the period. The Manufacturers Life Insurance Company owned about 0.11% of Dyne Therapeutics worth $3,815,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in DYN. AQR Capital Management LLC boosted its position in Dyne Therapeutics by 4.3% in the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company's stock valued at $300,000 after buying an additional 352 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock worth $26,000 after purchasing an additional 669 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company's stock worth $123,000 after purchasing an additional 709 shares during the last quarter. KBC Group NV lifted its position in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after purchasing an additional 751 shares during the period. Finally, Amalgamated Bank grew its position in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company's stock worth $99,000 after buying an additional 796 shares during the period. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Up 6.3 %

Shares of NASDAQ:DYN traded up $1.76 during trading on Friday, reaching $29.50. 1,123,240 shares of the company traded hands, compared to its average volume of 1,073,164. The firm has a market capitalization of $3.00 billion, a PE ratio of -8.29 and a beta of 1.09. Dyne Therapeutics, Inc. has a 52 week low of $10.33 and a 52 week high of $47.45. The company's 50 day moving average is $31.12 and its two-hundred day moving average is $35.40.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Chardan Capital restated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Oppenheimer reissued an "outperform" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Royal Bank of Canada initiated coverage on shares of Dyne Therapeutics in a research note on Tuesday, November 26th. They issued an "outperform" rating and a $45.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $50.82.

Insider Activity at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 782 shares of the firm's stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the transaction, the director now directly owns 15,962 shares of the company's stock, valued at $528,342.20. This trade represents a 4.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Dirk Kersten sold 79,411 shares of the company's stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares in the company, valued at $8,533,929.15. This trade represents a 25.33 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 176,257 shares of company stock valued at $6,193,718 in the last 90 days. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.